Distribution and case-fatality ratios by cell-type for @entity43 : A 22-year series of 562 XXXX with uniform current histological classification.

@entity43 @entity1 @entity1605 @entity5 @entity189 @entity1358 @entity6962
BACKGROUND: @entity43 is comprised of several different cell types reflecting different clinicopathologic features. Pathologic criteria for distinguishing cell types have evolved, and therefore non-contemporary literature on @entity43 may have limited current relevance. A new dualistic model of pathogenesis that distinguishes type I (endometrioid, mucinous, clear cell and low grade @entity189 ) from @entity1605 (high grade @entity189 and @entity6962 ) @entity5 has become widely accepted. METHODS: A cohort of 562 @entity1 with invasive @entity43 from a large community hospital practice was reviewed. Cell type, FIGO stage, mortality and interpathologist diagnostic reproducibility were analyzed. RESULTS: @entity43 were @entity1605 in 86% of cases while low stage @entity5 were most often type I. Only 1.7% of @entity5 were confirmed to be stage I with comprehensive surgical staging. @entity5 accounted for 85% of deaths, and @entity1358 , 5% of deaths. Cell type-specific case-fatality ratios for @entity5 were 62% and 79% for high grade @entity189 and @entity6962 , respectively. For type I @entity5 , case-fatality ratios were 38%, 36%, 27% and 13% for low grade serous, clear cell, endometrioid and @entity189 , respectively. The kappa value for diagnostic reproducibility among 3 gynecologic pathologists was 0.83. CONCLUSIONS: Current diagnostic criteria confirm that high grade @entity189 and @entity6962 account for the vast majority (85%) of @entity43 deaths. Cell type designation is highly reproducible among gynecologic pathologists. @entity5 are rarely stage I (<2%) when comprehensively staged by a gynecologic oncologist.
